- Home
- LDI vs AARD Comparison
LDI vs AARD Comparison
Compare LDI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- AARD
- Stock Information
- Founded
- LDI 2010
- AARD 2017
- Country
- LDI United States
- AARD United States
- Employees
- LDI N/A
- AARD N/A
- Industry
- LDI Finance: Consumer Services
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- LDI Finance
- AARD Health Care
- Exchange
- LDI Nasdaq
- AARD Nasdaq
- Market Cap
- LDI 221.2M
- AARD 242.9M
- IPO Year
- LDI 2021
- AARD 2025
- Fundamental
- Price
- LDI $1.96
- AARD $10.78
- Analyst Decision
- LDI Sell
- AARD Strong Buy
- Analyst Count
- LDI 2
- AARD 5
- Target Price
- LDI $2.05
- AARD $32.80
- AVG Volume (30 Days)
- LDI 2.0M
- AARD 46.3K
- Earning Date
- LDI 08-07-2025
- AARD 08-13-2025
- Dividend Yield
- LDI N/A
- AARD N/A
- EPS Growth
- LDI N/A
- AARD N/A
- EPS
- LDI N/A
- AARD N/A
- Revenue
- LDI $1,124,074,000.00
- AARD N/A
- Revenue This Year
- LDI $26.92
- AARD N/A
- Revenue Next Year
- LDI $15.27
- AARD N/A
- P/E Ratio
- LDI N/A
- AARD N/A
- Revenue Growth
- LDI 27.06
- AARD N/A
- 52 Week Low
- LDI $1.01
- AARD $4.88
- 52 Week High
- LDI $3.23
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- LDI 61.12
- AARD N/A
- Support Level
- LDI $1.77
- AARD N/A
- Resistance Level
- LDI $2.02
- AARD N/A
- Average True Range (ATR)
- LDI 0.18
- AARD 0.00
- MACD
- LDI 0.01
- AARD 0.00
- Stochastic Oscillator
- LDI 79.84
- AARD 0.00
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.